A Phase I Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)
Latest Information Update: 27 Jun 2022
At a glance
- Drugs ALLN 346 (Primary)
- Indications Hyperuricaemia
- Focus Adverse reactions; First in man
- Sponsors Allena Pharmaceuticals
- 04 Jun 2022 Results from two studies (NCT04236219 and NCT04829435) assessing safety, tolerability and evidence for lack of systemic absorption at various dose levels presented at the 23rd Annual Congress of the European League Against Rheumatism
- 09 Mar 2021 Status changed from active, no longer recruiting to completed, according to an Allena Pharmaceuticals media release.
- 30 Nov 2020 Status changed from recruiting to active, no longer recruiting, according to an Allena Pharmaceuticals media release.